BYETTA
LOE ApproachingPeptideexenatide synthetic
NDASUBCUTANEOUSINJECTABLE
Approved
Oct 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Mechanism of Action
Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. BYETTA is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the…
Indications (1)
Clinical Trials (4)
Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)
Started Feb 2011
2,948 enrolled
Type 2 Diabetes
Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans
Started Jan 2010
15 enrolled
Hyperlipidemia
Intravenous Exenatide (Byetta) During Surgery
Started Mar 2009
104 enrolled
EuglycemiaHypoglycemiaHyperglycemia
Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients
Started Feb 2008
41 enrolled
Type 2 Diabetes Mellitus